Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
04:05pm, Tuesday, 20'th Aug 2024
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel dis
Codexis Announces New Employment Inducement Grants
04:05pm, Friday, 16'th Aug 2024
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as appr
Codexis Publishes FY2023 Sustainability Disclosures
04:05pm, Thursday, 15'th Aug 2024
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript
11:01pm, Thursday, 08'th Aug 2024
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research K
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th Aug 2024
Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago.
Codexis to Report Second Quarter 2024 Financial Results on August 8
04:05pm, Thursday, 18'th Jul 2024
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second qua
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
04:05pm, Monday, 01'st Jul 2024
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswa
Codexis to Participate in Jefferies Global Healthcare Conference
04:25pm, Wednesday, 22'nd May 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Confe
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
04:05pm, Monday, 20'th May 2024
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, �
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
06:00am, Tuesday, 14'th May 2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enz
Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript
08:24pm, Thursday, 02'nd May 2024
Codexis, Inc. (NASDAQ:CDXS ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Office
Codexis to Report First Quarter 2024 Financial Results on May 2
04:05pm, Thursday, 18'th Apr 2024
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first qua
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
07:05am, Thursday, 11'th Apr 2024
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform Cobb adds RNA industry operations and commercial expertise to su
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
10:39pm, Wednesday, 28'th Feb 2024
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
07:51pm, Wednesday, 28'th Feb 2024
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
